Bortezomib for adults with hard-to-treat immune low platelets
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This Phase 2 trial tests whether bortezomib can safely increase platelet counts in adults with immune thrombocytopenia (ITP) that keeps coming back or doesn’t respond to standard treatments. It’s for people with very low platelets who still need treatment despite prior medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 19 or older.
- You have immune thrombocytopenia (ITP), primary or from another autoimmune condition.
- Your platelet count is below 30 (30 x 10^9/L) and you need active treatment.
- Your ITP has not fully responded (relapsed/refractory) to steroid treatment, or steroids can’t be used.
- You have tried at least two other ITP treatments besides steroids and also have tried two different treatments overall.
- You can take the study medicine safely based on pregnancy status, infection status, and organ/lab results (no active severe infection; no major liver/kidney limits).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study looks at zanubrutinib, a new medication, in people with immune thrombocytopenia (ITP) whose low platelet count has lasted more than 3 months and has not responded to prior steroid and other treatments. It may help raise platelets and reduce bleeding risk when other therapies have not worked.
This trial tests a chemotherapy combination that includes bortezomib for people whose acute lymphoblastic leukemia (ALL) has come back or not responded to previous treatments. It aims to offer a new option for those who haven't tried bortezomib before.
This study tests whether adding another medicine (telitacicept) to a standard platelet-boosting drug (eltrombopag) works better than eltrombopag alone for adults with ITP that hasn't improved with steroids. The goal is to help raise your platelet counts and reduce bleeding risk.
This study tests whether adding a second medication (Iguratimod) to a lower dose of rituximab helps people with a blood condition called ITP who have not responded well to steroids. The goal is to see if the combination is more effective than rituximab alone at raising and keeping platelet counts stable.
This study tests different doses of a drug called zanubrutinib (a BTK inhibitor) to find the best dose for adults with newly diagnosed ITP that hasn't been treated yet. It aims to see if this drug can safely boost platelet counts and reduce bleeding symptoms.
This trial tests a new drug (belantamab mafodotin) in adults with primary immune thrombocytopenia (ITP) who have already tried at least one other treatment. The goal is to see if the drug can safely raise platelet counts and reduce bleeding risk.
Hear when a new Relapsed/Refractory Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.